← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Thiazolidinediones for Diabetes: Evidence and Outcomes

Evidence related to thiazolidinedione therapies in diabetes studies.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/thiazolidinediones

Executive Summary

Thiazolidinediones evidence appears to center on HbA1c.

Among 13 indexed studies and 1 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
13
Evidence relationships
27
Interventions
1
Outcomes
27
Strong evidence signals
3
Mixed evidence areas
1

Key Findings

  1. 01

    Across 6 studies, Pioglitazone shows a consistent strong positive signal for HbA1c.

  2. 02

    Across 3 studies, Pioglitazone shows a evidence signal for Liver stiffness measure.

  3. 03

    Across 3 studies, Pioglitazone shows a moderate positive signal for Proportion achieving HbA1c <7.0%.

  4. 04

    Across 2 studies, Pioglitazone shows a consistent strong positive signal for Adiponectin.

Question Highlights

What outcomes has Thiazolidinediones been studied for?

HbA1c, Proportion achieving HbA1c <7.0%, and Liver stiffness measure are among the most studied areas in relation to Thiazolidinediones.

HbA1c, Proportion achieving HbA1c <7.0%, and Liver stiffness measure are among the best-supported options in the available evidence across 13 studies.

Consistency cannot yet be determined.

Read the full answer

Does Thiazolidinediones improve HbA1c?

Thiazolidinediones appears to improve HbA1c.

Strong evidence is based on 6 supporting studies.

Population details are unavailable.

Read the full answer

How does Thiazolidinediones compare across studied outcomes?

HbA1c, Proportion achieving HbA1c <7.0%, and Liver stiffness measure have available evidence for Thiazolidinediones, but the comparison requires review of the underlying studies.

Evidence is available for both HbA1c and Liver stiffness measure; the underlying studies are needed for a direct comparison.

Population details are unavailable.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

HbA1c · Liver stiffness measure · Proportion achieving HbA1c <7.0%

Evidence basis: 5 evidence pairs - 9 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Liver stiffness measure is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Liver stiffness measure · Proportion achieving HbA1c <7.0% · Controlled attenuation parameter

Evidence basis: 5 evidence pairs - 8 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Liver stiffness measure may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Liver stiffness measure · Proportion achieving HbA1c <7.0% · Adiponectin

Evidence basis: 5 evidence pairs - 7 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—